Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved QVAR® RediHaler™ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News

Teva Announces FDA Approval of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation AerosolAugust 7, 2017 8:00 AM UPDATE: Morgan Stanley Downgrades Teva Pharma (TEVA) to UnderweightAugust 7, 2017 6:23 AM Teva Pharma (TEVA) oncology assets said to draw Fresenius Mylan, Novartis interest - BloombergAugust 4, 2017 10:57 AM Teva Pharma (TEVA) Cut to 'BBB-' by Fitch; Outlook NegativeAugust 4, 2017 10:06 AM Teva Pharma (TEVA) PT Lowered to $28 at Deutsche BankAugust 4, 2017 8:41 AM Bernstein Downgrades Teva Pharma (TEVA) to Market PerformAugust 4, 2017 8:02 AM Teva Pharma (TEVA) PT Lowered to $26 at JefferiesAugust 4, 2017 7:50 AM Credit Suisse Downgrades Teva Pharma (TEVA) to NeutralAugust 4, 2017 6:01 AM RBC Capital Double Downgrades Teva Pharma (TEVA) to UnderperformAugust 4, 2017 5:54 AM Cowen Downgrades Teva Pharma (TEVA) to Market PerformAugust 4, 2017 5:51 AM